180 Life Sciences Corp. (ATNF)
Dopo ore:
| Chiusura precedente | 3,7300 |
| Aperto | 3,5500 |
| Denaro | 3,4800 x 900 |
| Lettera | 3,7000 x 900 |
| Min-Max giorno | 3,3500 - 3,6998 |
| Intervallo di 52 settimane | 1,1800 - 71,4000 |
| Volume | |
| Media Volume | 4.401.522 |
| Capitalizzazione | 13,193M |
| Beta (5 anni mensile) | 0,56 |
| Rapporto PE (ttm) | 4,06 |
| EPS (ttm) | 0,8700 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 80,00 |
- GlobeNewswire
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
PALO ALTO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced the publication of a review entitled ‘Treatments for early stage Dupuytren’s disease: an evidence-based approach’ in The Journal of Hand Surgery (European Volume). In the publication, Professor Jagdeep Nanchahal, chairman of the medical advisory board of 180 Life Sciences, and his colleague at the University of Oxford, describe the limitations for th
- GlobeNewswire
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
PALO ALTO, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company has engaged Kinexum, a strategic advisory firm, to support the Company in submitting a Marketing Authorisation Application (MAA) for adalimumab to treat progressive early-stage Dupuytren’s disease. The MAA will be submitted to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA or Agency). As part of the ap
- GlobeNewswire
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
PALO ALTO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on January 4, 2023 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”). As indicated in the letter, Nasdaq determined that for 1
